Table 10. Uptake of Risk-reducing Mastectomy (RRM) and/or Breast Screening Among BRCA1 and BRCA2 Mutation Carriers
| Study Citation | Study Population | Uptake of RRM | Uptake of Breast Screening Mammography and/or Breast MRI | Length of Follow-up | Comments |
| United States | |||||
| [200] | Carriers (n = 108)a | Carriers 37% | Mammography | Mean 5.3 y | Predictors of RRM were younger age, higher precounseling cancer distress, more recent diagnosis of breast or ovarian cancer, and intact ovaries. |
| Carriers affected 92% | |||||
| Carriers unaffected 82% | |||||
| Noncarriers (n = 60)a | Noncarriers 0% | Noncarriers 66% | |||
| Uninformative affected 89% | |||||
| MRI | |||||
| Uninformative (n = 206)a | Uninformative 6.8% | Carriers affected 51% | |||
| Carriers unaffected 46% | |||||
| Noncarriers 11% | |||||
| Uninformative 27% | |||||
| [201] | Carriers (n = 146)a | Carriers 13% | Not applicable | 12 mo | Intentions at test result disclosure predicted RRM decisions. |
| [202] | Carriers (n = 237)b | Carriers 23% | Not applicable | Mean 3.7 y | Women opting for RRM were <60 y, had a prior diagnosis of breast cancer, and also underwent RRSO. |
| Median time to RRM: 124 days from receiving results. | |||||
| [203] | Carriers (n = 37)a | Carriers 0% | Mammography | 24 mo | |
| Carriers 57% | |||||
| Noncarriers 49% | |||||
| Noncarriers (n = 92)a | Noncarriers 0% | Declined test 20% | |||
| Declined testing (n = 15)a | MRI | ||||
| Not evaluated | |||||
| International | |||||
| [204] | Carriers (n = 101)a | Carriers 6.9% | Mammography | 5 y | Noncarriers often continued screening. |
| Carriers 59% | |||||
| Noncarriers aged 30–39 y 53% | |||||
| Noncarriers (n = 145)a | Noncarriers 0% | MRI | |||
| Carriers 31% | |||||
| Noncarriers 4.8% | |||||
| [205] | Carriers (n = 70)a | Carriers 11% | Mammography | 3 y | |
| Carriers 89% | |||||
| MRI | |||||
| Not evaluated | |||||
| [206] | Carriers (N = 2,677)a | Carriers 18% (unaffected) | Mammography | 3.9 y; range 1.5–10.3 y | Large differences in uptake of risk management options by country. |
| Carriers 87% | |||||
| MRI | 1,294 participants had a personal history of breast cancer. | ||||
| Carriers 31% | |||||
| MRI = magnetic resonance imaging; RRSO = risk-reducing salpingo-oophorectomy. | |||||
| aSelf-report as data source. | |||||
| bMedical records as data source. | |||||
| cData source not specified. |
References
- Schwartz MD, Isaacs C, Graves KD, et al.: Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118 (2): 510-7, 2012. [PUBMED Abstract]
- O'Neill SC, Valdimarsdottir HB, Demarco TA, et al.: BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat 124 (3): 755-64, 2010. [PUBMED Abstract]
- Beattie MS, Crawford B, Lin F, et al.: Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 13 (1): 51-6, 2009. [PUBMED Abstract]
- Botkin JR, Smith KR, Croyle RT, et al.: Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118 (3): 201-9, 2003. [PUBMED Abstract]
- Julian-Reynier C, Mancini J, Mouret-Fourme E, et al.: Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. Eur J Hum Genet 19 (5): 500-6, 2011. [PUBMED Abstract]
- Phillips KA, Jenkins MA, Lindeman GJ, et al.: Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70 (3): 198-206, 2006. [PUBMED Abstract]
- Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122 (9): 2017-22, 2008. [PUBMED Abstract]
